In vivo reversibility of multidrug resistance by the MDR-modulator dexniguldipine (niguldipine derivative B859-35) and by verapamil

Journal of Experimental Therapeutics and Oncology

Volumn 1, Issue 1, 1996, Pages 23-29

  Dietel, M ^a   Boss, H ^c   Reymann, A ^b   Pest, S ^a   Seidel, A ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c ALTANA PHARMA AG   (Germany)

Author keywords

Dexniguldipine; Multidrug resistance; Reversibility; Verapamil

Indexed keywords

ANTINEOPLASTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; GLYCOPROTEIN P; NIGULDIPINE; VERAPAMIL;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL CULTURE; DRUG RESISTANCE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MOUSE; NUDE MOUSE; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED; VERAPAMIL;

EID: 0029677298     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Weinstein RS, Kuszak JR, Kluskens LF, Coons JS. P-glycoproteins in pathology: The multidrug resistance gene family in humans. Hum Pathol 21: 34-48, 1990.
2. Dietel M. What's new in cytostatic drug resistance and pathology? Pathol Res Pract 187: 892-905, 1991.
3. Yin MB, Bankusli I, Rustum YM. Mechanisms of the in vivo resistance to adriamycin and modulation by calcium channel blockers in mice. Cancer Res 49: 4729-4733, 1989.
4. Kiue A, Sano T, Suzuki KI, et al. Activities of newly synthesized dihydropyridines in overcoming of vincristine resistance, calcium antagonism, and inhibition of photoaffinity labeling of P-glycoprotein in rodents. Cancer Res 50: 310-317. 1990.
5. Kramer RA, Onwukeme C. A human solid tumor model for evaluating the efficacy of chemomodulators of multidrug resistance. AADR Special Conference in Cancer Res Banff, Alberta, Canada: B43, 1991 (abstr).
6. Sato W, Fukazawa N, Suzuki T, Yusa K, Tsuruo T. Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073. Cancer Res 51: 2420-2424, 1991.
7. Murren JR, Hait WN. Why haven't we cured multidrug resistant tumors? Oncology Res 4: 1-6, 1992.
8. Dietel M, Herzig I, Reymann A, Schäfer B, Bunge A, Heidebrecht HJ, Seidel A. Secondary combined resistance to the multidrug resistance reversing activity of cyclosporin A in the cell line F4-6RADR-CsA. J Cancer Res Clin Oncol 120: 263-271, 1994.
9. Höllt V, Kouba M, Dietel M, Vogt G. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem Pharmacol 43: 2601-2608, 1992.
10. Hofmann J, Ueberall F, Egle A, Grunicke H. B859-35, a new drug with antitumor activity reverses multidrug resistance. Int J Cancer 47: 870, 1991.
11. Reymann A, Looft G, Woermann C, Dietel M, Erttmann R. Reversal of multidrug resistance in Friend leukemia cells by dexniguldipine-HCl. Cancer Chemother Pharmacol 32: 25-30, 1993.
12. Kartner N, Evernden-Porelle D, Bradley G, Ling V. Detection of P-glycoprotein in multidrug-resistant cells by monoclonal antibodies. Nature 316: 820-823, 1985.
13. Dietel M, Arps H, Lage H, Niendorf A. Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res 50: 6100-6106, 1990.
14. Tallarida RJ, Murray RB. Manual of pharmacologic calculations. New York, Berlin, Heidelberg, Tokyo: Springer, 1987.
15. Mickisch GH, Licht T, Merlino GT, Gottesman MM, Pastan I. Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: efficacy, potency, and toxicity. Cancer Res 51: 5417-5424, 1991.
16. Mickisch GH, Siegsmund M, Gottesman MM, Pastan I. Use of MDR-transgenic mice to test chemosensitizing agents that reverse multidrug resistance. Ann Oncol 3: 71, 1992.
17. Foxwell BMJ, Mackie A, Ling V, Ryffel B. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Molecular Pharmacol 36: 543-546, 1989.
18. Gekeler V, Willisch A, Mitterdorfer J, Noller A, Häußermann K, Hoffmann J. MDR modulating and antineoplastic effects of the pure dihydropyridine enantiomer B859-35, and its pyridine metabolite. 2. Joint Meeting AACR and Jpn Cancer Ass 1992 (abstr).
19. 1-adrenoceptors. Eur J Pharm (Mol Pharm Section) 172: 131-145, 1989.
20. Karck U, Rathgeb F, Wurst W, Meerpohl HG. Open phase I/II study of standard FEC therapy with B8509-035, a novel drug blocking the p-170 glycoprotein. 85. Proc. 7th NCI-EORTC Symp. on New Drugs in Cancer Chemotherapy, Amsterdam, 1992 (abstr).
21. Wolf M, Lenze H, Schroeder M, Maasberg M, Wurst W, Rathgeb F, Havemann K. Application of the dihydropyridine derivative B8509-35 in resistant small cell lung cancer. Eur J Cancer 27 (Suppl): R1128, 1991.
22. Beck WT. Modulators of p-glycoprotein-associated multidrug resistance. In: Ozols RF, (ed). Molecular and clinical advances in anticancer drug resistance. Boston: Kluwer Academic Publ., p 151, 1991.